Mechanisms underlying the J-curve for diastolic blood pressure: Subclinical myocardial injury and immune activation.
暂无分享,去创建一个
L. Shaw | P. Wilson | A. Quyyumi | V. Vaccarino | S. Epstein | Y. Ko | Wesley T. O’Neal | S. Hayek | Jonathan H Kim | L. Sperling | Jonathan H. Kim | A. Alkhoder | P. Sandesara | M. M. Gafeer | A. Tahhan | E. Stahl | M. Topel | Ayman Alkhoder | Matthew L. Topel | P. Wilson
[1] P. Whelton,et al. Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control , 2018, Circulation.
[2] A. Quyyumi,et al. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes. , 2017, Atherosclerosis.
[3] Faisal Rahman,et al. The J-shaped Curve for Blood Pressure and Cardiovascular Disease Risk: Historical Context and Recent Updates , 2017, Current Atherosclerosis Reports.
[4] S. Yusuf,et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials , 2017, The Lancet.
[5] J. Wojta,et al. Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure. , 2017, JACC. Heart failure.
[6] D. Newby,et al. High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease , 2016, Journal of the American College of Cardiology.
[7] Deepak L. Bhatt,et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study , 2016, The Lancet.
[8] J. Coresh,et al. 60 A comparison of HFrEF vs HFpEF’s clinical workload and cost in the first year following hospitalisation and enrollment in a disease management program , 2016, Journal of the American College of Cardiology.
[9] C. Yuan,et al. Blood Pressure Is a Major Modifiable Risk Factor Implicated in Pathogenesis of Intraplaque Hemorrhage: An In Vivo Magnetic Resonance Imaging Study , 2016, Arteriosclerosis, thrombosis, and vascular biology.
[10] Deepak L. Bhatt,et al. Pulse Pressure and Risk for Cardiovascular Events in Patients With Atherothrombosis: From the REACH Registry. , 2016, Journal of the American College of Cardiology.
[11] A. Kjær,et al. Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV‐1‐infected patients: a nested case‐control study , 2015, HIV medicine.
[12] A. Quyyumi,et al. Soluble Urokinase Receptor and Chronic Kidney Disease. , 2015, The New England journal of medicine.
[13] J. Jeppesen,et al. suPAR: A New Biomarker for Cardiovascular Disease? , 2015, The Canadian journal of cardiology.
[14] Christopher M O'Connor,et al. Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. , 2015, Journal of the American College of Cardiology.
[15] Christopher M O'Connor,et al. Treatment of Hypertension in Patients With Coronary Artery Disease: A Scientific Statement From the American Heart Association, American College of Cardiology, and American Society of Hypertension , 2015, Hypertension.
[16] A. Quyyumi,et al. Soluble Urokinase Plasminogen Activator Receptor Level Is an Independent Predictor of the Presence and Severity of Coronary Artery Disease and of Future Adverse Events , 2014, Journal of the American Heart Association.
[17] P. Greenland,et al. Recommendations for treating hypertension: what are the right goals and purposes? , 2014, JAMA.
[18] Jackson T. Wright,et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). , 2014, JAMA.
[19] T. Hansen,et al. CRP and suPAR are differently related to anthropometry and subclinical organ damage. , 2013, International journal of cardiology.
[20] A. Quyyumi,et al. Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes. , 2013, Journal of the American College of Cardiology.
[21] S. Solomon,et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. , 2013, Journal of the American College of Cardiology.
[22] M. Persson,et al. Soluble Urokinase Plasminogen Activator Receptor is Associated With Inflammation in the Vulnerable Human Atherosclerotic Plaque , 2012, Stroke.
[23] B. Fuhrman. The urokinase system in the pathogenesis of atherosclerosis. , 2012, Atherosclerosis.
[24] J. Vincent,et al. suPAR as a prognostic biomarker in sepsis , 2012, BMC Medicine.
[25] E. Ford. Trends in Mortality From All Causes and Cardiovascular Disease Among Hypertensive and Nonhypertensive Adults in the United States , 2011, Circulation.
[26] T. Hansen,et al. Increased Plasma Soluble uPAR Level Is a Risk Marker of Respiratory Cancer in Initially Cancer-Free Individuals , 2011, Cancer Epidemiology, Biomarkers & Prevention.
[27] S. Bangalore,et al. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. , 2010, European heart journal.
[28] T. Hansen,et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population , 2010, Journal of internal medicine.
[29] G. Panjrath,et al. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? , 2009, Journal of the American College of Cardiology.
[30] Carl J Pepine,et al. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. , 2009, European heart journal.
[31] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[32] G. Mancia,et al. Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous? , 2006, Annals of Internal Medicine.
[33] G. Hansson. Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.
[34] Carl J Pepine,et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. , 2003, JAMA.
[35] 修 飯村,et al. 慢性糸球体腎炎患者に対するAngiotensin-Converting Enzyme InhibitorとAngiotensin II Receptor Blockerの併用による抗蛋白尿効果 , 2003 .
[36] P. Ridker. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. , 2003, Circulation.
[37] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[38] C. Mulrow,et al. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? , 1991, JAMA.
[39] M. Marcus,et al. The effect of hypertension and left ventricular hypertrophy on the lower range of coronary autoregulation. , 1988, Circulation.
[40] R. Kerber,et al. The effect of cardiac hypertrophy on the coronary collateral circulation. , 1985, Circulation.
[41] WGAusten,et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association , 1975 .
[42] R. Frye,et al. A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. , 1975, Circulation.